A discovery by Hudson Institute researchers sheds light on the potential reasons why exposing unborn babies affected by fetal growth restriction (FGR) to sildenafil may have led to unexpected neonatal deaths.
Sildenafil was originally studied for use in high blood pressure before it was marketed as a treatment for erectile dysfunction. The drug, which dilates blood vessels and increases blood flow, can also be taken postnatally by women to treat prolonged high blood pressure. Sildenafil has therefore been studied as a potential treatment for FGR, a condition in which babies grow poorly in the womb.
Hudson Institute researchers investigated how sildenafil impacts the developing fetus, a study carried out in pre-clinical models. It was found to have a negative and potentially harmful effect.
“This finding was important because we show that the use of a drug that is safe in one context, i.e. postnatally, is not in another,” said first author Dr Ishmael Inocencio, postdoctoral scientist, Neonatal Brain Protection, at Hudson Institute.
At the same time the Hudson Institute study was taking place, a large multi-centre clinical trial in humans called the STRIDER study was halted early when a number of babies died.
The STRIDER trial was investigating whether using sildenafil during pregnancy for those babies affected by fetal growth restriction could improve placental function and babies’ growth by increasing blood flow.
It was not understood at the time whether the medication caused the increased death rates in babies, however the Hudson Institute-led study published in The Journal of Physiology provides a crucial insight.
“Fetal growth restriction occurs when the womb does not supply the developing baby with enough nutrients and oxygen to ensure that it grows to its full potential,” Dr Inocencio said.
“If there is low blood flow in the mother’s placenta, there is a lower level of oxygen available to the growing baby. The fetus has a mechanism to respond to this by redirecting the blood flow to essential organs such as the brain and heart, and away from non-essential organs – called ‘brain sparing’,” he said.
“We found that far from having a positive effect, giving sildenafil impaired this mechanism, decreased the already low oxygen levels, and exacerbated fetal growth restriction,” he said.
Study leader Dr Beth Allison, Senior Research Scientist, Perinatal Transition at Hudson Institute said fetal growth restriction occurs in about one in seven pregnancies in Australia.
“Our research shows that consideration of the consequences on the developing fetus should be paramount when giving medicinal interventions to the mother during pregnancy,” Dr Allison said.
“Our findings suggest the use of sildenafil in the clinical treatment for placental insufficiency should be approached with caution.”
- Affects 1 in 7 – more than 20,000 – Australian babies per year
- Up to 20 per cent of babies born globally affected each year
- Can cause cardiovascular disease, lung and brain injury, cognitive, learning and behavioural problems, cerebral palsy and autism
- FGR increases the risk of stillbirth 20-fold and is a principal cause of perinatal death